Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 75.40

+5.5%

Nov 11 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2002)	10/24/2007 12:19:50 PM
From: Jibacoa	Read Replies (1) of 3722

HNAB wants to continue its recent UT.<g> bigcharts.marketwatch.com It presented data for its Alocrest, OPTISOME at the Molecular Targets and Cancer Therapeutics International Conference sponsored by the AACR, the NCI & the EORTC. The data from the PI for Alocrest, demonstrated anti-tumor activity with 3 of 11 patients achieving stable disease. Alocrest has been relatively well tolerated. The ongoing PI is enrolling adult subjects with confirmed solid tumors refractory to standard therapy or for which no standard therapy was known to exist, or with relapsed and/or refractory NHL or HD. HNAB needs to close its March 23 & Feb 21 DGs.<g> bigcharts.marketwatch.com HNAB doesn't have significant LTD & the insiders reportedly hold around 10%. The stock did well for a while from Sep 2005 to its H of $12.94 in Apr 2006 <g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next